申请人:Eli Lilly and Company
公开号:US10519158B2
公开(公告)日:2019-12-31
The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
本发明涉及式(I)的药物化合物或其药学上可接受的盐或组合物,以及它们用于治疗疼痛、呼吸系统疾病以及抑制瞬态受体电位 A1 离子通道(TRPA1)的方法。